Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GM-CSF + entecavir
- Development stage
- Unknown
- Lead developer
- The Fifth Medical Center of the PLA General Hospital
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
GM-CSF + entecavir is an experimental combination therapy being investigated by Beijing 302 Hospital (The Fifth Medical Center of PLA General Hospital) for the treatment of chronic hepatitis B (CHB). This regimen combines the immunomodulatory effects of Granulocyte Macrophage-colony Stimulating Factor (GM-CSF), a biologic cytokine that stimulates the production and activity of macrophages and dendritic cells, with the potent antiviral activity of entecavir, a nucleoside analog that inhibits HBV DNA polymerase. The rationale behind this combination is to enhance the host's cellular immune response against the hepatitis B virus, potentially leading to higher rates of HBsAg seroconversion and functional cure compared to entecavir monotherapy. Clinical trials, such as NCT03164889, evaluate the efficacy of this combination in achieving HBsAg loss in CHB patients.
- Other names
- GM-CSF + ETVGranulocyte Macrophage-colony Stimulating Factor + Entecavir
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on GM-CSF + entecavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GM-CSF + entecavir.